IRD Opus Genetics, Inc.

CIK 0001228627 50 ready 8-Ks latest June 16, 2026, 4:11 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 2 baseline

Ready 8-Ks 50

Latest filing June 16, 2026, 4:11 PM ET

Top materiality 0.90

Event mix other_material ×23 · earnings ×12 · leadership ×6

Sentiment 20 pos · 4 neg · 26 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for IRD

Highest-materiality recent filing

Ocuphire completes merger with Opus Genetics; renamed Opus Genetics with $37M pro forma cash

October 22, 2024, 7:59 PM ET M&A materiality 0.90 neutral item 1.01 item 5.03 item 2.01 item 2.02 item 3.02 item 3.03 item 5.02 item 7.01 item 9.01 ◈ executive_change ×5◈ Governance Changes ×2◈ M&A Transactions

Merger closed Oct 22; Ocuphire issued ~5.24M common shares and 14,145 Series A Preferred (convertible into ~14.1M common) to Opus securityholders.
Pro forma cash ~$37M as of Sep 30, 2024; cash runway expected into 2026.

Read filing →

June 16, 2026, 4:11 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Opus Genetics details five IRD gene therapy programs; four data readouts expected in 2027, cash runway to 2029

OPGx-RDH12 enters clinical testing in Q4 2026; OPGx-MERTK Q1 2027; OPGx-RHO H2 2027.
May 12, 2026, 7:01 AM ET earnings materiality 0.70 negative item 2.02 item 9.01 ◈ Earnings Releases

Opus Genetics Q1 net loss $65.5M; cash $60M; enters $35M Oberland debt facility

Net loss $65.5M ($0.75 per share) vs $8.2M loss a year ago; includes non-cash warrant liability fair value change.
April 24, 2026, 7:59 PM ET debt materiality 0.70 neutral item 2.03 ◈ Debt Financings

Opus Genetics closes $35 million initial tranche of $155 million senior secured notes

Initial $35 million tranche funded on April 21, 2026; notes mature April 21, 2033.
April 7, 2026, 7:59 PM ET debt materiality 0.80 positive item 1.01 item 3.02 item 7.01 item 9.01 ◈ Material Agreements

Opus Genetics secures up to $155M debt facility from Oberland Capital; cash runway extended into 2029

$155M senior secured notes: $35M initial (closing Apr 20, 2026), $35M option in 12 mos, $35M milestone-based (LCA5), $50M mutual agreement.
March 10, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01 ◈ Earnings Releases

Opus Genetics reports FY2025 net loss $49.6M; cash $70.1M; PDUFA date Oct 2026

Net loss $49.6M ($0.80/sh) vs $57.5M ($2.15/sh) in 2024; revenue $14.2M from Viatris collab.
February 19, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 2.02 item 3.02 item 5.03 item 8.01 item 9.01 ◈ Material Agreements ×2◈ Equity Issuances

Opus Genetics raises $25M via Series B convertible preferred; pro forma cash $70M

Closed private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred at $3.39/share for $25M.
December 19, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01

Opus Genetics partner Viatris files sNDA with FDA for presbyopia treatment

Viatris filed sNDA for Phentolamine Ophthalmic Solution 0.75% to treat presbyopia.
November 12, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Opus Genetics Q3 net loss $17.5M; cash >$50M; LCA5 gene therapy gains FDA RMAT

Q3 net loss of $17.5M ($0.25/sh) vs $7.5M ($0.29/sh) in prior year; revenue $3.1M from Viatris collaboration.
November 6, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Opus Genetics raises $23M in direct offering and secures FDA guidance for LCA5 gene therapy trial

$23M registered direct offering led by Perceptive Advisors and Balyasny Asset Management; closes Nov 7, 2025.
November 6, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Opus Genetics raises ~$23M in registered direct offering with Perceptive, Nantahala, Balyasny

Purchase agreement with affiliates of Perceptive, Nantahala, and Balyasny for 3.83M shares and 7.18M pre-funded warrants at $2.09/$2.0899.
September 30, 2025, 7:59 PM ET other material materiality 0.65 positive item 7.01 item 8.01 item 9.01

Opus Genetics LCA5 gene therapy shows 0.3 logMAR improvement in pediatric cohort; durable 18-month adult data

Three pediatric participants (ages 16-17) showed group avg 0.3 logMAR visual acuity improvement and >1 log unit cone sensitivity improvement on FST.
August 25, 2025, 7:59 PM ET other material materiality 0.60 positive item 3.02

Opus Genetics raises $3.5M in private placement led by board chair for gene therapy manufacturing

Issued 3,138,338 shares at ~$1.11/sh in private placement; gross proceeds $3.5M.
August 13, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Opus Genetics Q2 net loss narrows to $7.4M; FDA grants RMAT for OPGx-LCA5

Net loss $7.4M ($0.12/share) vs $7.8M ($0.30) in Q2 2024; revenue $2.9M from Viatris collaboration.
June 26, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Opus Genetics VEGA-3 Phase 3 trial meets primary endpoint for presbyopia treatment

27.2% of patients on drug achieved ≥15-letter DCNVA gain vs 11.5% placebo (p<0.0001) at 12h post-dose on Day 8.
June 25, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

CFO Nirav Jhaveri departs Opus Genetics; Amy Rabourn appointed interim principal financial officer

CFO Nirav Jhaveri terminated without cause on June 25, 2025; no disagreement with auditors or management.
June 23, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

Opus Genetics gets up to $2M non-dilutive funding from RD Fund for MERTK gene therapy program

Up to $2 million non-dilutive funding from RD Fund (Foundation Fighting Blindness) for OPGx-MERTK preclinical program.
June 20, 2025, 7:59 PM ET other material materiality 0.65 positive item 1.01

Opus Genetics secures up to $2M nondilutive funding from Foundation Fighting Blindness for MERTK gene therapy

Up to $2,000,000 nondilutive funding from Foundation Fighting Blindness Retinal Degeneration Fund for MERTK gene therapy program.
May 15, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Opus Genetics Q1 net loss $8.2M; cash $41.8M; LCA5 gene therapy shows sustained 12-month efficacy

Net loss of $8.2M ($0.24 per share) vs $7.1M ($0.29) in Q1 2024.
March 31, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Opus Genetics reports FY2024 net loss of $57.5M; gene therapy pipeline advances

Net loss of $57.5M ($2.15/sh) vs $10.0M in 2023; revenue $11M from Viatris license.
March 24, 2025, 7:59 PM ET other material materiality 0.85 positive item 3.02 item 8.01 item 9.01

Opus Genetics closes $20M public stock/warrant offering; CEO & chairman buy $1.5M unit

Public offering of 12,219,736 units (share + warrant) at $0.95/unit plus 8,832,895 pre-funded warrants at $0.9499; gross proceeds ~$20M.
March 20, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Opus Genetics reports preliminary FY 2024 net loss of $56.8M, cash burn $25.6M

Net loss for FY 2024 expected to be approximately $56.8 million.
March 20, 2025, 7:59 PM ET other material materiality 0.60 positive item 5.03 item 8.01 item 9.01 ◈ Governance Changes

Opus Genetics amends bylaws to enhance stockholder rights; sues Sandoz over RYZUMVI

Bylaws amended: written consent requirements eliminated; 20% threshold to call special meeting.
March 4, 2025, 6:59 PM ET litigation materiality 0.75 negative item 8.01

Opus Genetics receives Sandoz Paragraph IV notice challenging six RYZUMVI patents

Sandoz filed ANDA for generic RYZUMVI; alleges six Orange Book patents invalid/unenforceable/non-infringed.
January 7, 2025, 6:59 PM ET M&A materiality 0.65 neutral item 9.01

Opus Genetics files audited FY2023 financials of acquired Opus Inc.; net loss $9.75M, cash $180k

FY2023 audited: net loss $9.75M, no revenue; accumulated deficit $25.1M.
November 12, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Opus Genetics reports Q3 net loss of $7.5M; pro forma cash $37M after Opus acquisition

Net loss $7.5M ($0.29/share) vs net income $5.6M in Q3 2023; revenue $3.9M down from $11.9M.
October 22, 2024, 7:59 PM ET M&A materiality 0.90 neutral item 1.01 item 5.03 item 2.01 item 2.02 item 3.02 item 3.03 item 5.02 item 7.01 item 9.01 ◈ executive_change ×5◈ Governance Changes ×2◈ M&A Transactions

Ocuphire completes merger with Opus Genetics; renamed Opus Genetics with $37M pro forma cash

Merger closed Oct 22; Ocuphire issued ~5.24M common shares and 14,145 Series A Preferred (convertible into ~14.1M common) to Opus securityholders.
August 13, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Ocuphire Q2 net loss $7.8M ($0.30/sh); cash $41.4M; VEGA-3 recruiting for presbyopia

Net loss $7.8M ($0.30/sh) vs $5.0M ($0.24) in Q2 2023; revenue from collaborator license $1.1M vs $3.7M.
June 13, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.03 item 5.07 item 9.01

Ocuphire Pharma shareholders approve share increase to 125M, reject Lincoln Park issuance and officer exculpation

Shareholders approved amendment to increase authorized common stock from 75M to 125M, effective June 12.
May 10, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ocuphire Q1 net loss $7.1M ($0.29/sh); cash $47.2M; RYZUMVI launch yields first royalty

Net loss of $7.1M ($0.29 per share) vs $5.8M ($0.28) in Q1 2023.
May 10, 2024, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Ocuphire Pharma presents NPDR subset analysis from ZETA-1 Phase 2 trial for APX3330

Subset analysis: 3% of APX3330 vs 20% of placebo had ≥3-step worsening on binocular DRSS at Week 24.
March 8, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ocuphire Pharma reports FY 2023 net loss of $10M; advances APX3330 Phase 3 and RYZUMVI launch

Cash $50.5M at Dec 31, 2023; management expects to fund operations into mid-2025.
February 16, 2024, 6:59 PM ET leadership materiality 0.60 positive item 5.02 item 9.01 ◈ executive_change

Ocuphire Pharma appoints Nirav Jhaveri as CFO and Ash Jayagopal as Chief Scientific Officer

Nirav Jhaveri appointed CFO effective Feb 12, 2024; base salary $410k, equity awards: 210k options + 140k RSUs.
November 13, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Ocuphire Q3 net income $5.6M ($0.26 EPS); revenue $11.9M; FDA agrees Phase 3 endpoint for APX3330; RYZUMVI approved

Q3 net income $5.6M ($0.26 basic EPS) vs $4.5M loss ($0.22 loss) a year ago; revenue $11.9M from $0.
November 2, 2023, 7:59 PM ET regulatory materiality 0.85 positive item 7.01 item 8.01 item 9.01

Ocuphire successful End-of-Phase 2 meeting with FDA for oral APX3330 in diabetic retinopathy

FDA agreed on Phase 3 primary endpoint: ≥3-step worsening on binocular DRSS; SPA to be submitted.

Executive changes

Appointed

Benjamin R. Yerxa

President

IRD · Opus Genetics, Inc.

Effective: 2024-10-22
Filed: October 22, 2024, 7:59 PM ET

Dr. Yerxa, age 58, has also been appointed to serve as Ocuphire’s President, effective October 22, 2024.

Appointed

Benjamin R. Yerxa

Director

IRD · Opus Genetics, Inc.

Effective: 2024-10-22
Filed: October 22, 2024, 7:59 PM ET

Dr. Benjamin R. Yerxa, Ph.D., Dr. Jean Bennett, Ph.D., M.D., and Dr. Adrienne Graves, Ph.D., were appointed as members of the Board

Appointed

Jean Bennett

Director

IRD · Opus Genetics, Inc.

Effective: 2024-10-22
Filed: October 22, 2024, 7:59 PM ET

Dr. Benjamin R. Yerxa, Ph.D., Dr. Jean Bennett, Ph.D., M.D., and Dr. Adrienne Graves, Ph.D., were appointed as members of the Board

Departed

Jay Pepose

Director

IRD · Opus Genetics, Inc.

Effective: 2024-10-22
Filed: October 22, 2024, 7:59 PM ET

Dr. Jay Pepose resigned from the Board, effective immediately after the time of the filing of the First Merger Certificate of Merger

Appointed

Adrienne Graves

Director

IRD · Opus Genetics, Inc.

Effective: 2024-10-22
Filed: October 22, 2024, 7:59 PM ET

Dr. Benjamin R. Yerxa, Ph.D., Dr. Jean Bennett, Ph.D., M.D., and Dr. Adrienne Graves, Ph.D., were appointed as members of the Board

Appointed

Nirav Jhaveri

Chief Financial Officer

IRD · Opus Genetics, Inc.

Effective: 2024-02-12
Filed: February 16, 2024, 6:59 PM ET

On February 14, 2024, Ocuphire Pharma, Inc., (the “Company”) announced the appointment of Nirav Jhaveri as the Company’s Chief Financial Officer (“CFO”), effective February 12, 2024

Role change

Ronil Patel

Chief Business Officer

IRD · Opus Genetics, Inc.

Effective: 2023-12-01
Filed: December 6, 2023, 6:59 PM ET

On December 1, 2023, the Board of Directors (the "Board" ) of Ocuphire Pharma, Inc. (the "Company" ) promoted Ronil Patel , age 40, as the Company’s Chief Business Officer, effective as of December 1, 2023.

Appointed

Joseph Schachle

Chief Operating Officer

IRD · Opus Genetics, Inc.

Effective: 2023-11-27
Filed: November 27, 2023, 6:59 PM ET

On November 22, 2023, the Board of Directors (the “Board”) of Ocuphire Pharma, Inc. (the “Company”) appointed Joseph Schachle, age 58, as the Company’s Chief Operating Officer, effective as of November 27, 2023.

Appointed

Dr. George Magrath

Chief Executive Officer

IRD · Opus Genetics, Inc.

Effective: 2023-11-01
Filed: November 1, 2023, 7:59 PM ET

On October 30 , 2023, the Board of Directors (the “Board” ) of Ocuphire Pharma, Inc. (the “Company” ) appointed Dr. George Magrath, age 39, as the Company’s Chief Executive Officer, effective as of November 1, 2023.

Departed

Sooch

Chief Executive Officer

IRD · Opus Genetics, Inc.

Effective: 2023-04-19
Filed: June 14, 2023, 7:59 PM ET

Pursuant to the Separation and Release Agreement, Ms. Sooch will receive certain benefits in connection with Ms. Sooch being terminated without cause on April 19, 2023.

Appointed (interim)

Richard Rodgers

interim President and Chief Executive Officer

IRD · Opus Genetics, Inc.

Effective: 2023-04-19
Filed: April 21, 2023, 7:59 PM ET

On April 19, 2023, the Board of Directors o f the Company (the “ Board ”) appointed Richard Rodgers as the Company’s interim President and Chief Executive Officer effective as of April 19 , 2023.

Departed

Mina Sooch

President and Chief Executive Officer

IRD · Opus Genetics, Inc.

Effective: 2023-04-19
Successor: Richard Rodgers
Filed: April 21, 2023, 7:59 PM ET

On April 19, 2023, Ocuphire Pharma, Inc. (the “ Company ”) terminated the employment of Mina Sooch, the President and Chief Executive Officer of the Company.

Earnings & guidance

2026-Q1 EPS reported -$0.75 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.60 · Most common event other_material

20 positive 4 negative 26 neutral

source · IRD on sec.gov